COMPANY
Cytonics Corporation
Timeline
- Trial start Phase 1: Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee source ↗
- Trial start Phase 1/Phase 2: APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee source ↗
- Trial start Not phased (device or behavioral study): Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06263270 | Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee | Phase 1 | Completed | Jun 1, 2024 | Mar 15, 2025 (actual) |
| NCT02210468 | APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | 2015-05 | 2016-07 (estimated) |
| NCT02209662 | Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | 2014-10 | 2015-10 (estimated) |
NIH awards 3
- NIH award 5R44AR060676-03 FY2012: $719,440 awarded for that fiscal year; activity R44 (SBIR); PI HANNA, LEWIS S.; recipient as written: CYTONICS CORPORATION, JUPITER, FL. Diagnostic Biomarkers for Radicular Pain source ↗
- NIH award 9R44AR060676-02 FY2011: $882,440 awarded for that fiscal year; activity R44 (SBIR); PI HANNA, LEWIS S.; recipient as written: CYTONICS CORPORATION, JUPITER, FL. Diagnostic Biomarkers for Radicular Pain source ↗
- NIH award 1R43NS065669-01A1 FY2010: $192,300 awarded for that fiscal year; activity R43 (SBIR); PI SCUDERI, GAETANO JOHN; recipient as written: CYTONICS CORPORATION, JUPITER, FL. Diagnostic Biomarkers for Radicular P source ↗